Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112861 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL1305955 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL1306887 | 0.87 | CA12 (0.46) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL1306885 | 0.87 | CA12 (0.46) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL10267296 | 0.87 | CA12 (0.46) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL8106690 | 0.84 | CA12 (0.50) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16796406 | 0.82 | CA12 (0.49) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16519665 | 0.82 | CA12 (0.49) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL8434086 | 0.81 | CA12 (0.48) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL8611221 | 0.81 | LMNA (0.49) | SMN1; SMN2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053590-B2 | Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-11-08 | — | — | US | disclosed |
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7514578-B2 | Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, ADM2, MTHFD2 | SMN1; SMN2 3293/4885CA12 198/4885CA1 61/4885 |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, DAO, ADM2 | SMN1; SMN2 3638/4885CA12 128/4885CA1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.